Here is a question worth asking before you read another dosing chart: was the number tested, or was it just repeated until it sounded official?
With MK-677, almost every milligram figure circulating online falls into the second category. The compound has been through real human trials, so real data exists. But those trials were built to test disease outcomes in sick and frail people, not to find a “sweet spot” for someone wanting more muscle. When a forum thread or a product page hands you a precise number and calls it optimal, it is manufacturing certainty the science never produced. This piece sorts what was actually measured from what has simply been repeated enough times to feel true.
One thing to get out of the way early: MK-677 is not FDA-approved. And the part of this story people skip past fastest, the blood sugar part, is the part that matters most.
Tier one: the one number a trial actually used
If you want a dose with a real study behind it, there is exactly one candidate: 25 mg, once daily. That is what the largest trial in this drug’s history used, 563 patients with Alzheimer’s disease, dosed for twelve months [P1]. It shows up across the older-adult research generally. The drug’s roughly 24-hour half-life is why once-daily dosing is pharmacologically sensible rather than arbitrary.
So 25 mg clears the first bar: it was actually tested. It does not clear the second bar, which is whether it worked. In that 563-person trial, 25 mg a day pushed IGF-1 up by about 73%, reliably, and did nothing measurable for the disease it was being tested against [P1]. In a separate two-year trial in healthy older adults, the same general dosing range produced about 1.1 kg of added lean mass, and the researchers stated flatly that it “did not result in changes in strength or function” [P2].
Read that twice if you need to. The most-studied dose is not a proven winning dose. It is a dose with excellent documentation of what it does to a hormone panel and rather thin documentation of what it does for a person. That gap should temper anyone’s urge to chase a higher number “for better results,” because the trial evidence does not show that a higher number produces better results. It shows a moving IGF-1 line and a mostly unmoved outcome.
Tier two: what does scale reliably with dose, and it isn’t muscle
This is where the evidence gets less ambiguous, unfortunately in the wrong direction.
Two effects track with MK-677 dosing consistently across the research: blood sugar and fluid retention. Neither is cosmetic.
On blood sugar: in the two-year trial, insulin sensitivity declined and average fasting glucose rose by about 5 mg/dL [P2]. That is not a fluke result buried in a subgroup, it is a repeated finding, and it lines up with what the U.S. Department of Defense’s supplement-safety program documents, listing increased fasting blood glucose and a heightened hyperglycemia risk among MK-677’s known effects [P4]. If you are prediabetic, insulin resistant, or diabetic, this is your headline risk, full stop, and it does not improve with a bigger dose.
On fluid: the same trial recorded water retention and mild lower-leg swelling as a common effect [P2], and the Department of Defense advisory separately flags “the potential for congestive heart failure in certain patients” as a documented concern [P4]. That warning emerged from work in frail, elderly patients, so a healthy 28-year-old should read it with proportion rather than alarm. But the direction of the effect is not in dispute. This drug pushes fluid retention, and fluid retention is not the kind of thing to test-drive at a self-selected higher dose because the effect “didn’t feel like enough” last week.
Put those two together and a plain rule falls out: the lowest dose that produces a noticeable effect is the sound choice, because every increment upward buys more of the risk that is actually documented (glucose, fluid) without buying more of the benefit that the trials actually measured (which, again, at these doses, was modest at best).
Tier three: the folklore layer
Some of what circulates about MK-677 dosing is not wrong, exactly. It just was never tested, and the honest thing is to say so plainly rather than dress it up as protocol.
People using MK-677 outside a clinical setting commonly report running below the 25 mg trial figure, often somewhere around 10 to 25 mg daily. That is a description of what people do, not an endorsement of a number, because no trial has established that 12.5 mg is “enough” for a given goal or that 25 mg is “too much.” What can be said is that a lower dose likely carries a lower share of the metabolic and fluid burden, and that burden is the one worth minimizing.
There is one genuine kernel in the early literature worth naming honestly. A small study of eight healthy young volunteers under caloric restriction found MK-677 shifted them toward positive nitrogen balance, a marker associated with muscle preservation while dieting [P3]. That is a real, if narrow, signal. It is not evidence for a recreational muscle-building protocol, and running a higher dose than that eight-person study used does not extend the finding into territory anyone has measured.
A few practical notes, offered without pretending they’re science:
Night dosing is common, on the logic that it’s easier to sleep through the appetite spike and it loosely tracks the body’s natural overnight growth hormone pulse. No trial shows evening dosing beats morning dosing for outcomes. Treat it as a comfort preference, not an optimization.
Expect hunger. MK-677 acts on the ghrelin receptor, so appetite increase is close to guaranteed, and it was among the most frequent effects in the long trial, though it tended to ease over months [P2]. If you’re not prepared to manage that, no amount of dose-tweaking will matter more than your fridge will.
Don’t stack blind. The Department of Defense advisory specifically notes that products containing MK-677 are frequently combined with SARMs, or mislabeled as one [P4]. Every additional compound is another variable nobody is watching. One unverified drug at a conservative dose is a smaller gamble than several.
The problem no dosing chart can solve
Here’s the part that actually undercuts everything above, and it’s structural rather than a matter of willpower.
If the MK-677 in front of you came from an unsupervised gray-market seller, you do not know what’s actually in the vial. “For research use only” powder has been verified by no one with any obligation to get it right. It might be underdosed, overdosed, or contaminated, and the only way you’d find out is by being the experiment. Which means every careful decision in this article, every “I’ll start low and titrate slowly,” rests on a milligram figure printed by a party with zero accountability. You can be as disciplined as you like about dose and still be wrong, because the input was never trustworthy to begin with.
That is a stronger argument against gray-market sourcing than any single side effect is, and it’s the argument dosing pages conveniently leave out.
What actually changes the risk calculus
Supervision doesn’t work because a clinician hands down a magic number, since as established, no such number exists. It works because it changes what can go wrong. A clinician reviewing your history can decide whether MK-677 is appropriate at all, work with a product whose dose is a known quantity, and actually watch the two things that matter, glucose and fluid status, over time. That’s not marketing language, that’s just what medical oversight does that self-dosing structurally cannot.
FormBlends is worth naming as one legitimate option operating on that model: a licensed telehealth provider, not a chemical storefront, with a physician evaluation preceding anything being dispensed and a licensed pharmacy filling the prescription. Supervised MK-677 through that route runs roughly $50 to $150 a month, which is not obviously more expensive than an unverified gray-market vial of the same molecule. The premium, such as it is, buys you a dose you can trust and someone paying attention to your labs.
If you go that route, keep it simple: log your dose, appetite, any swelling, sleep quality, anything that feels off, and bring it to your check-ins. A basic logging tool like the FormBlends tracker app can hold that record so the conversation with a clinician is built on data rather than recollection. It’s a logging tool. Not a prescription, not a checkout.
None of this makes MK-677 an approved drug. Compounded is not the same claim as FDA-approved, and that distinction should stay in view no matter which provider you use.
The honest bottom line
The most-studied MK-677 dose, 25 mg daily, is the dose that failed its largest trial [P1] and produced lean mass without any gain in strength or function in the other major trial [P2]. That’s not a springboard for a bigger number. It’s a caution sign.
What scales reliably with dose is risk, not reward: worse glucose control and more fluid retention as the number climbs [P2][P4], with no trial evidence that going higher buys proportionally more benefit. Don’t self-escalate a compound that moves your blood sugar and carries a cardiac flag. Don’t stack blind. And recognize that an unverified vial makes every dosing decision downstream of it unreliable, no matter how carefully you calculate.
If you’re going to do this at all, the version that actually protects you is the supervised one, where the milligrams are a known quantity and someone is watching the numbers that can hurt you. Every figure in this piece traces to a specific trial or advisory, cited below. Go pull them and check the math yourself. That’s not a rhetorical flourish, it’s an invitation.
What people usually want to know
What is the most common MK-677 dose in human studies?
25 mg once daily is the figure used most often, including in the largest trial, which ran it in 563 patients for twelve months [P1]. It’s the only number a real clinical study put into real people at scale, but it’s worth being precise about what that means: it’s the most-documented dose, not a proven winning dose for physique goals. In that same trial it did nothing for the condition being tested [P1].
Is a higher dose of MK-677 more effective?
No trial shows that going past the studied range produces more benefit, while the documented downsides do scale with dose. Worse blood sugar control and fluid retention increase as the dose climbs [P2][P4], and the lean-mass effect seen at standard doses came without any gain in strength or function [P2]. The defensible position is the lowest dose that produces a noticeable effect, not the biggest number you can tolerate.
When is the best time of day to take MK-677?
Many people dose at night to sleep through the appetite surge and roughly track the body’s overnight growth hormone pulse, but no trial demonstrates evening dosing outperforms morning dosing. Given the roughly 24-hour half-life, timing is a comfort choice, not an optimization one. If nighttime hunger disrupts your sleep, that’s a legitimate reason to move it earlier.
Does MK-677 raise blood sugar?
Yes. In the two-year trial, insulin sensitivity fell and average fasting glucose rose about 5 mg/dL [P2], and the U.S. Department of Defense’s supplement-safety program lists increased fasting glucose and elevated hyperglycemia risk among documented effects [P4]. Anyone prediabetic, insulin resistant, or diabetic should treat this as the central risk, and raising the dose does not help.
Can you trust the dose printed on a gray-market MK-677 vial?
No, and this is arguably the most important point in the whole conversation. Unregulated “research use only” powder has not been verified by anyone, so it can be underdosed, overdosed, or contaminated without your knowledge. The only setting where the milligrams are actually a known quantity is supervised compounding through a licensed provider, where a clinician sets the dose and a licensed pharmacy fills it. FormBlends operates on that model rather than as a chemical storefront.
Is MK-677 a steroid?
No. It’s a non-peptide, orally active ghrelin mimetic, meaning it binds the ghrelin receptor and prompts the pituitary to release more growth hormone. It has none of the androgen-receptor activity that defines anabolic steroids, so its hormonal risk profile is a different category, though it carries its own concerns around insulin sensitivity and fluid retention.
Does MK-677 increase testosterone?
Not directly. It raises growth hormone and IGF-1 but does not act on the hypothalamic-pituitary-gonadal axis the way anabolic compounds do. Some users describe a secondary sense of improved recovery they credit to testosterone, but the human trial data doesn’t show meaningful testosterone changes from MK-677. If testosterone support is the actual goal, this is the wrong tool for it.
Is MK-677 a peptide?
Not technically. It’s a small-molecule peptidomimetic, designed to mimic the ghrelin signal but chemically distinct from a true peptide. That distinction has a practical consequence: it survives stomach acid and can be taken orally, while true peptides like GHRP-2 or ipamorelin break down in digestion and require injection. The mechanism rhymes; the chemistry and delivery route don’t.
What should someone actually know before taking MK-677 for the first time?
Three things stand out. First, sourcing is a genuine safety problem, since gray-market capsules are frequently misdosed or contaminated, and a physician-supervised compounding route, such as through FormBlends, gets you verified dosing and medical accountability instead. Second, MK-677 reliably raises fasting glucose in some people, so a baseline glucose check is a reasonable precaution. Third, water retention and increased appetite show up in nearly everyone early on. They’re not side effects to push through by raising the dose.
References
- Growth hormone secretagogue MK-677: no clinical effect on Alzheimer’s disease progression in a randomized trial of 563 patients dosed at 25 mg daily for 12 months, despite a roughly 73% IGF-1 increase at 12 months. Sevigny JJ, et al. Neurology, 2008;71(21):1702-1708. https://pubmed.ncbi.nlm.nih.gov/19015485/
- Effects of an oral ghrelin mimetic (MK-677) on body composition and clinical outcomes in healthy older adults: a 2-year randomized trial. Fat-free mass increased about 1.1 kg with no improvement in strength or function; insulin sensitivity decreased and fasting glucose rose about 5 mg/dL; appetite increase and transient lower-extremity edema were the most frequent side effects. Nass R, et al. Annals of Internal Medicine, 2008;149(9):601-611. https://pubmed.ncbi.nlm.nih.gov/18981485/
- MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism (positive nitrogen balance during caloric restriction in eight healthy young volunteers). Murphy MG, et al. Journal of Clinical Endocrinology and Metabolism, 1998;83(2):320-325.
- MK-677 (ibutamoren) is an unapproved drug and growth hormone secretagogue, not a SARM but often combined with or mislabeled as one; documented effects include increased fasting blood glucose, heightened risk of hyperglycemia, effects on insulin sensitivity, and the potential for congestive heart failure in certain patients. U.S. Department of Defense, Operation Supplement Safety.
